Polymers for colon specific drug delivery

Journal of Controlled Release

Volumn 39, Issue 2-3, 1996, Pages 327-338

  Schacht, Etienne ^a   Gevaert, An ^a   Kenawy, El Refaie ^a   Molly, Koen ^b   Verstraete, Willy ^b   Adriaensens, Peter ^c   Carleer, Robert ^c   Gelan, Jan ^c  

^a GHENT UNIVERSITY   (Belgium)

^b Laboratory of Microbial Ecology   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

5 Aminosalicylic acid; Azo polymer; Coating; Degradation; Human colon; Prodrug colon targeting

Indexed keywords

HYDRAZINE DERIVATIVE; MESALAZINE; POLYMER;

BIOREACTOR; COLON; COMPUTER SIMULATION; CONFERENCE PAPER; DRUG RELEASE; DRUG STRUCTURE; ECOSYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHILICITY; HYDROPHOBICITY; INTESTINE ABSORPTION; OXIDATION REDUCTION REACTION; PHARMACEUTICS; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 0029971849     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00184-0     Document Type: Conference Paper

References (46)

1. M.A. Peppercorn and P. Goldman, The role of intestinal bacteria in the metabolism of salicylazosulfapyridine, J. Pharmacol. Exp. Ther. 181 (1972) 555-562.
2. G. Järnerot, Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 37 (1989) 73-86.
3. D.R. Friend, Colon-specific drug delivery, Adv. Drug Deliv. Rev. 7 (1991) 149-199.
4. D.L. Geier and P.B. Miner Jr, New therapeutic agents in the treatment of inflammatory bowel disease, Am. J. Med. 93 (1992) 199-208.
5. M. Kamm and A. Senapati. Drug management of ulcerative colitis, Br. Med. J. 305 (1992) 35-38.
6. B. Crotty and D.P. Jewell, Drug therapy of ulcerative colitis, Br. J. Clin. Pharmacol. 34 (1992) 189-198.
7. M.J. Dew, P.J. Hughes, M.G. Lee, B.K. Evans and J. Rhodes, An oral preparation to release drugs in the human colon, Br. J. Clin. Pharmacol. 14 (1982) 405-408.
8. K.W. Schroeder, W.J. Tremaine and D.M. Ilstrup, Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis, N. Engl. J. Med. 317 (1987) 1625-1629.
9. H. Schröder and A.K. Johansson, Redox potential in caecal contents of the rat and azo reduction of salicylazosulphapyridene, Xenobiotica 3 (1973) 233-246.
10. T. Miyadera, Biological formation and reactions of hydrazo, azo and azoxy groups, in: S. Patai (Ed.), The Chemistry of Hydrazo, Azo and Azoxy Compounds, Part 1, Wiley, New York, 1975, p. 495.
11. R. Walker, Metabolism of azo group: a review of literature, Food Cosmet. Toxicol. 8 (1970) 659-676.
12. J.L. Radomski and T.J. Mellinger, Absorption, Fate and excretion in rats of soluble azo dyes, J. Pharmacol. Exp. Ther. 136 (1962) 259.
13. B. Dieckhues, Reductive splitting of azo-dyes by bacteria, Zentralbl. Bakteriol. Parasitenkd. 180 (1960) 244.
14. A.T. Fuller, Is p-amino benzene sulfonamide the active aent in Prontosil therapy?. Lancet 1 (1937) 194.
15. J.W. Daniel, The excretion and metabolism of edible food colors 4 (1962) 572.
16. R.R. Scheline, B. Longberg, The absorption, metabolism and excretion of sulfonated azo dye, acid yellow, by rats, Acta Pharmacol. Toxicol. 23 (1965) 1.
17. H. Schroeder and D.E. Campbell, Absorption, metabolism and excretion of salicylazosulfopyridine in man, Clin. Pharmacol. Ther. 13 (1972) 539.
18. D. Dubru and K.L. Wright. Reduction of azo food dyes in cultures of Proteus vulgaris, Xenobiotica 5 (1975) 563.
19. T.E. Hanohan, B.A. Enderlin and T.M. Parkinson, Intestinal absorption of polymeric derivatives of the food dyes Sunset Yellow and Tartriazine in rats, Xenobiotica 7 (1977) 765.
20. J.P Brown, Reduction of polymeric azo and nitro dyes by intestinal bacteria, Appl. Environ. Microbiol. 41 (1981) 1283.
21. K.T. Chung, G.E. Funk and M. Egan, Azo dye reduction by anaerobes, Appl. Environ. Microbiol. 5 (1976) 558.
22. E.E. Askelöf, N. Svart and H.C. Willstaedt, Heterocyclic sulfon amido azo compounds, US Patent 2396 (1946) 145.
23. J.B. Kirsner, Observation on the medical treatment of inflammatory bowel desease, J. Am. Med. Assoc. 243 (1980) 557-564.
24. U. Klotz, K. Maier, C. Fischer and K. Heinkal, Therapeutic efficiancy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohns desease, N. Engl. J. Med. 303 (1980) 1499-1502.
25. T.M. Parkinson, J.P. Brown and R.E. Wingard, US Patent 4,190,176, February 20 (1980).
26. T.M. Parkinson, J.P. Brown and R.E. Wingard. US Patent 4,298,595, November 3 (1981).
27. J.P. Brown, G.V. McCarraugh, T.M. Parkinson, R.E. Wingard Jr and A.B. Onderdonk, Polymeric drug for treatment of inflammatory bowel disease, A. J. Med. Chem. 26 (1983) 1300-1307.
28. D. Gallant and E. Schacht, Macromolecular prodrugs of 5-aminosalicylic acid. 1. Azoconjugates, Makromol. Chem. 191 (1990) 529-536.
29. P. Kopeckova and J. Kopecek, Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers by azoreductase in-vitro, Makromol. Chem. 191 (1990) 2037-2045.
30. M. Saffran, G.S. Kumar, C. Savariar, J.C. Burnham, F. Williams and D.C. Neckers, A new approach to the oral administration of insulin and other peptide drugs, Science 233 (1986) 1081-1084.
31. M. Saffran, G.S. Kumar, D.C. Neckers, J. Pena, R.H. Jones and J.B. Field, Biodegradable azopolymer coating for oral delivery of peptide drugs, Biochem. Soc. Trans. 18 (1990) 752-754.
32. H. Bröndsted, J. Kopecek, Hydrogels for site-specific drug delivery to the colon - in vitro and in vivo degradation, Pharm. Res. 9 (1992) 1540-1545.
33. G. Vanden Mooter, C. Samijn and R. Kinget, Azo polymers for colon-specific drug delivery, Int. J. Pharm. 87 (1992) 37-46.
34. E. Schacht and I. Wilding. Process for the preparation of azo-and/or disulfide-containing polymers. Eur. Patent 0,513,035 B1 (1991).
35. Y. Kimura, S. Kim and A. Nishiura, Novel polyurethanes, Eur. Patent 0,398,472 A2 (1990).
36. Y. Kimura, Y. Makita, T. Kumagai, H. Yamane, T. Kitao, H. Sasatani and S.I. Kim, Degradation of azo-containing Polyurethane by the action of intestinal flora, Polymer 33 (1992) 5294-5299.
37. K. Molly, M. Vande Woestyne and W. Verstraete, Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem, Appl. Microbiol. Biotechnol 39 (1993) 254-258.
38. J. Pato, M. Azori and F. Tüdös, Polymeric Prodrugs, 1. Synthesis by direct coupling of drugs, Makromol. Chem., Rapid Commun. 3 (1982) 643-647.
39. P. Neri, G. Antoni, F. Benvenuti, F. Cocola and G. Gazzei, Synthesis of α,β;-poly[(2-hydroxyethyl)-DL-aspartamide], a new plasma expander, J. Med. Chem. 16 (1973) 893-897.
40. G. Antoni, P. Neri, T.G. Pedersen and M. Ottesen, Hydrodynamic properties of a new plasma expander: polyhydroxyethylaspartamide, Biopolymers 13 (1974) 1721-1729.
41. M.L. Tomlinson, Reduction of p-nitrobenzoic acid to hydrazo-and azobenzene-4,4′-dicarboxylic acids by means of glucose, J. Chem. Soc., 756 (1946).
42. D. Callant and E. Schacht, Macromolecular prodrugs of 5-aminosalicylic acid, azo-conjugates, Makromol. Chem. 191 (1990) 529-536.
43. 5N-(2-hydroxyethyl)-L-glutamine] and coupling with bioactive agents, Makromol. Chem. 193 (1992) 3023-3030.
44. D.P. Nelson and L.J. Mata, Bacterial flora associated with the human gastro-intestinal mucosa, Gastroenterology 58 (1970) 56.
45. P. Bhat, M.J. Albert, P. Rajan, J. Ponniak, V.I. Matliaz and S.J. Baker, Bacterial flora of the jejenum: a comparison of luminal aspirate and mucosal biopsy, J. Med. Microbiol. 13 (1980) 247.
46. H. Schröder and A.K. Johansson, Redox potential in caecal contents of the rat and azo reduction of salicylazosulfopyridine, Xenobiotica 3 (1973) 233.